By combining tumor organoids of various glioma subtypes with in vivo expansion in the brain microenvironment, we present a cohort of 40 PDOX generated from primary and paired recurrent gliomas with mixed genetic backgrounds including, among others, IDH1 mutation and distinct EGFR variants. This evidence concerns the gene EGFR and central nervous system cancer.